INTRODUCTION: Based on radiobiology evidence, hypofractionated radiotherapy has the potential of improving treatment outcome in prostate cancer patients. In this study, we evaluated the safety, in terms of acutetoxicity, of using moderate hypofractionated radiotherapy delivered with Helical Tomotherapy (HT) to treat prostate cancer patients. MATERIALS AND METHODS: Between December 2012 and April 2014, 42 consecutive patients were treated with hypofractionated radiotherapy using HT. All patients received 70 Gy in 28 fractions to PTV1, which included the prostate. In the intermediate risk group, 61.6 Gy were delivered to PTV2, which included the seminal vesicles. In high risk patients, the pelvic nodes were added (PTV3) and received 50.4 Gy. Acute toxicity was recorded prospectively with RTOG and Common Terminology Criteria for Adverse Events 3.0, retrospectively with CTCAE 4.0. Expanded Prostate Cancer Index Composite (EPIC) was measured at baseline and 3 months after end of treatment, to investigate health related quality of life with regards to bladder and gastrointestinal function. RESULTS: Acute toxicity was acceptable, independently from the system used to score side effects. Moderate genitourinary toxicity was more frequent than gastrointestinal toxicity. No correlation between acute side effects and patients' characteristics or physical dose parameters was registered. EPIC evaluation showed a negligible difference in urinary and bowel function post-treatment, that did not reach statistical significance. CONCLUSIONS: Our experience confirms the safety of moderate hypofractionation delivered with HT in prostate cancer patients with low, intermediate and high risk.
INTRODUCTION: Based on radiobiology evidence, hypofractionated radiotherapy has the potential of improving treatment outcome in prostate cancerpatients. In this study, we evaluated the safety, in terms of acutetoxicity, of using moderate hypofractionated radiotherapy delivered with Helical Tomotherapy (HT) to treat prostate cancerpatients. MATERIALS AND METHODS: Between December 2012 and April 2014, 42 consecutive patients were treated with hypofractionated radiotherapy using HT. All patients received 70 Gy in 28 fractions to PTV1, which included the prostate. In the intermediate risk group, 61.6 Gy were delivered to PTV2, which included the seminal vesicles. In high risk patients, the pelvic nodes were added (PTV3) and received 50.4 Gy. Acute toxicity was recorded prospectively with RTOG and Common Terminology Criteria for Adverse Events 3.0, retrospectively with CTCAE 4.0. Expanded Prostate Cancer Index Composite (EPIC) was measured at baseline and 3 months after end of treatment, to investigate health related quality of life with regards to bladder and gastrointestinal function. RESULTS: Acute toxicity was acceptable, independently from the system used to score side effects. Moderate genitourinary toxicity was more frequent than gastrointestinal toxicity. No correlation between acute side effects and patients' characteristics or physical dose parameters was registered. EPIC evaluation showed a negligible difference in urinary and bowel function post-treatment, that did not reach statistical significance. CONCLUSIONS: Our experience confirms the safety of moderate hypofractionation delivered with HT in prostate cancerpatients with low, intermediate and high risk.
Entities:
Keywords:
Prostate; Quality of Life; Side effects; Tomotherapy
Authors: David Dearnaley; Isabel Syndikus; Georges Sumo; Margaret Bidmead; David Bloomfield; Catharine Clark; Annie Gao; Shama Hassan; Alan Horwich; Robert Huddart; Vincent Khoo; Peter Kirkbride; Helen Mayles; Philip Mayles; Olivia Naismith; Chris Parker; Helen Patterson; Martin Russell; Christopher Scrase; Chris South; John Staffurth; Emma Hall Journal: Lancet Oncol Date: 2011-12-12 Impact factor: 41.316
Authors: S Hynds; C K McGarry; D M Mitchell; S Early; L Shum; D P Stewart; J A Harney; C R Cardwell; J M O'Sullivan Journal: Br J Radiol Date: 2010-12-15 Impact factor: 3.039
Authors: F Alongi; A Fogliata; P Navarria; A Tozzi; P Mancosu; F Lobefalo; G Reggiori; A Clivio; L Cozzi; M Scorsetti Journal: Strahlenther Onkol Date: 2012-09-29 Impact factor: 3.621
Authors: Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-19 Impact factor: 7.038
Authors: Benjamin L King; Wayne M Butler; Gregory S Merrick; Brian S Kurko; Joshua L Reed; Brian C Murray; Kent E Wallner Journal: Int J Radiat Oncol Biol Phys Date: 2010-06-03 Impact factor: 7.038
Authors: Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-15 Impact factor: 7.038
Authors: Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-04 Impact factor: 7.038
Authors: Una M O'Doherty; Helen A McNair; Andrew R Norman; Elizabeth Miles; Simon Hooper; Mark Davies; Naomi Lincoln; Jan Balyckyi; Peter Childs; David P Dearnaley; Robert A Huddart Journal: Radiother Oncol Date: 2006-06-16 Impact factor: 6.280
Authors: Giuseppe Ferrera; Salvatore D'Alessandro; Francesco Cuccia; Vincenzo Serretta; Giovanna Trapani; Gianfranco Savoca; Gianluca Mortellaro; Antonio Lo Casto Journal: J Cancer Res Clin Oncol Date: 2021-09-30 Impact factor: 4.553
Authors: R Mazzola; S Fersino; A Fiorentino; F Ricchetti; N Giaj Levra; G Di Paola; G Sicignano; S Naccarato; R Ruggieri; F Alongi Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405